The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ005/TCOG0902.
Satoshi Oizumi
Honoraria - AstraZeneca
Research Funding - Lilly
Shunichi Sugawara
No relevant relationships to disclose
Koichi Minato
No relevant relationships to disclose
Toshiyuki Harada
No relevant relationships to disclose
Akira Inoue
Research Funding - AstraZeneca; Lilly
Yuka Fujita
No relevant relationships to disclose
Makoto Maemondo
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Hirohisa Yoshizawa
Honoraria - AstraZeneca; Lilly
Research Funding - AstraZeneca; Lilly
Kazuhiko Ito
No relevant relationships to disclose
Akihiko Gemma
Honoraria - AstraZeneca
Masaru Nishitsuji
No relevant relationships to disclose
Masao Harada
No relevant relationships to disclose
Hiroshi Isobe
No relevant relationships to disclose
Ichiro Kinoshita
No relevant relationships to disclose
Satoshi Morita
Honoraria - AstraZeneca; Lilly
Kunihiko Kobayashi
Honoraria - AstraZeneca
Koichi Hagiwara
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Minoru Kurihara
No relevant relationships to disclose
Toshihiro Nukiwa
No relevant relationships to disclose